Biodexa Pharmaceuticals PLC has officially announced the appointment of PKF Littlejohn LLP as its new independent registered public accounting firm, effective October 31, 2024. This change follows the resignation of the previous auditor, Forvis Mazars LLP (formerly known as Mazars LLP), which took effect on October 25, 2024. The decision came after Forvis Mazars LLP informed the company of their intention to resign and a subsequent tender process was conducted to select a new auditor. The Audit Committee and the Board of Directors of Biodexa Pharmaceuticals assessed the commercial terms and expertise of the tender participants before approving PKF Littlejohn LLP's appointment. Forvis Mazars LLP's audit reports for the fiscal years ended December 31, 2022, and 2023 did not contain any adverse opinion or disclaimer...Show More

Biodexa Pharmaceuticals PLC has officially announced the appointment of PKF Littlejohn LLP as its new independent registered public accounting firm, effective October 31, 2024. This change follows the resignation of the previous auditor, Forvis Mazars LLP (formerly known as Mazars LLP), which took effect on October 25, 2024. The decision came after Forvis Mazars LLP informed the company of their intention to resign and a subsequent tender process was conducted to select a new auditor. The Audit Committee and the Board of Directors of Biodexa Pharmaceuticals assessed the commercial terms and expertise of the tender participants before approving PKF Littlejohn LLP's appointment. Forvis Mazars LLP's audit reports for the fiscal years ended December 31, 2022, and 2023 did not contain any adverse opinion or disclaimer and were not qualified or modified, except for a modification regarding the company's ability to continue as a going concern. There were no disagreements or reportable events between the company and Forvis Mazars LLP during the fiscal years or the interim period leading up to the resignation. Biodexa Pharmaceuticals has provided Forvis Mazars LLP with the disclosures made in this report and has included a letter from Forvis Mazars LLP to the SEC, dated November 1, 2024, as Exhibit 16.1. The company plans to use this report to satisfy its reporting obligations under Item 16F(a) of its Form 20-F for the year ending December 31, 2024, and to incorporate it by reference into its Form 20-F as necessary.